Saturday 17 October 2026
Export TAK’s income statement to Excel — free account
Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
19.67
0.22
+1.13%
Follow TAK
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 7 | 3 | 5 | 7 | 5 | 8 | 5 | 5 | 4 |
P/E ratio |
0.00 | 65.94 | 9.76 | 116.50 | 16.02 | 21.80 | 21.40 | 42.87 | 49.75 | 27.45 |
Altman Z-Score |
1.96 | 2.47 | 0.70 | 0.84 | 1.61 | 0.99 | 1.10 | 0.96 | 1.10 | 1.03 |
P/S ratio |
2.38 | 2.40 | 1.92 | 1.56 | 1.90 | 1.41 | 1.72 | 1.45 | 1.59 | 1.94 |
Altman Z″-Score (non-manufacturers) |
2.06 | 3.19 | 1.35 | 1.16 | 2.86 | 1.62 | 1.43 | 1.48 | 1.44 | 1.23 |
P/FCF ratio |
3.98 | 3.99 | 4.57 | 11.06 | 7.39 | 5.36 | 20.07 | 25.38 | 6.87 | 5.33 |
P/Operating CF |
22.26 | 22.30 | 17.05 | 27.71 | 15.64 | 13.10 | 21.51 | 21.76 | 8.47 | 9.22 |
Beneish M-Score |
(2.49) | (2.74) | (1.89) | (2.48) | (2.89) | (2.42) | (2.89) | (2.66) | (2.80) | (2.65) |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 25 |
P/B ratio |
2.13 | 2.02 | 1.76 | 1.09 | 1.17 | 0.89 | 1.09 | 0.85 | 0.95 | 1.17 |
Price to Tangible BV |
7.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
2.51 | 2.79 | 2.29 | 2.91 | 3.03 | 2.38 | 2.67 | 2.48 | 2.55 | 2.83 |
EV/EBITDA |
0.00 | 5.92 | 7.49 | 14.00 | 3.17 | 8.14 | 9.30 | 11.22 | 11.90 | 10.59 |
EV/Operating CF |
3.50 | 3.85 | 4.36 | 14.30 | 9.60 | 7.57 | 10.99 | 14.76 | 7.15 | 5.34 |
EV/FCF |
4.21 | 4.63 | 5.44 | 20.62 | 11.82 | 9.06 | 31.18 | 43.28 | 11.06 | 7.77 |
Quick Ratio |
0.60 | 1.09 | 0.59 | 0.66 | 1.02 | 0.75 | 0.50 | 0.51 | 0.45 | 0.53 |
Current Ratio |
0.92 | 1.46 | 1.22 | 1.13 | 1.53 | 1.21 | 0.97 | 1.11 | 1.01 | 1.09 |
Net Debt/EBITDA |
2.03 | 1.44 | 10.53 | 6.49 | 1.19 | 3.32 | 3.32 | 4.64 | 3.72 | 5.84 |
Debt/Assets |
26.28% | 24.00% | 41.46% | 39.73% | 35.90% | 32.97% | 31.40% | 32.06% | 31.69% | 31.47% |
Debt/Equity |
0.59 | 0.49 | 1.11 | 1.08 | 0.90 | 0.76 | 0.69 | 0.67 | 0.65 | 0.66 |
Asset Turnover |
0.45 | 0.41 | 0.23 | 0.25 | 0.25 | 0.27 | 0.27 | 0.28 | 0.31 | 0.30 |
Operating CF/Net income |
2.27 | 2.02 | 3.01 | 15.14 | 2.69 | 4.88 | 3.08 | 4.97 | 9.80 | (6.83) |
Capex/Depreciation |
(0.49) | (0.69) | (0.31) | (0.35) | (0.34) | (0.32) | (0.95) | (0.65) | (0.50) | (0.57) |
Interest Coverage |
6.70 | 7.57 | 2.46 | 0.61 | 10.05 | 2.77 | 2.89 | 0.97 | 1.63 | 0.02 |
| 6.14% | 9.27% | 3.04% | 0.90% | 7.67% | 4.13% | 4.81% | 2.05% | 1.48% | (2.12%) | |
| 2.96% | 4.34% | 1.21% | 0.34% | 2.95% | 1.72% | 2.13% | 0.96% | 0.72% | (1.02%) | |
ROIC |
3.58% | 5.75% | 1.26% | 0.68% | 17.72% | 3.15% | 3.01% | 1.15% | 1.94% | 0.03% |
Return on Tangible Assets |
27.06% | 21.28% | 5.88% | 2.63% | 15.71% | 11.33% | 19.72% | 6.45% | 5.44% | (6.41%) |
Average Days of Receivables |
93.73 | 88.40 | 130.38 | 87.05 | 92.76 | 74.08 | 61.78 | 59.72 | 57.78 | 70.99 |
Research and Development Expense of Revenue |
18.03% | 18.38% | 17.56% | 14.96% | 14.25% | 14.74% | 15.73% | 17.12% | 15.94% | 15.00% |
Selling, General and Administrative Expense of Revenue |
35.74% | 35.48% | 34.22% | 29.31% | 27.38% | 24.83% | 24.76% | 24.72% | 24.11% | 24.06% |
Intangible Assets out of Total Assets |
0.48 | 0.50 | 0.65 | 0.64 | 0.62 | 0.62 | 0.65 | 0.64 | 0.63 | 0.59 |
Share Based Compensation of Revenue |
0.00% | 1.05% | 0.96% | 0.88% | 1.18% | 1.22% | 1.51% | 1.66% | 1.59% | 1.62% |
Graham Net Nets |
(0.12) | (0.25) | (0.29) | (1.09) | (0.83) | (0.97) | (0.75) | (0.85) | (0.70) | (0.52) |
Graham Number |
0.00 | 0.00 | 0.00 | 6.40 | 19.99 | 15.46 | 16.20 | 10.73 | 15.16 | 15.01 |
Earnings Yield |
(1.61%) | 1.52% | 10.25% | 0.86% | 6.24% | 4.59% | 4.67% | 2.33% | 2.01% | 3.64% |
Free Cash Flow Yield |
25.10% | 25.05% | 21.88% | 9.04% | 13.53% | 18.66% | 4.98% | 3.94% | 14.56% | 18.77% |
Revenue per Share |
10.31 | 10.20 | 9.82 | 9.72 | 9.62 | 10.16 | 9.60 | 9.40 | 9.58 | 9.44 |
Operating CF per Share |
1.56 | 2.18 | 1.54 | 1.98 | 3.04 | 3.20 | 2.33 | 1.58 | 2.21 | 2.18 |
Capex per Share |
(0.65) | (0.72) | (0.39) | (0.61) | (0.57) | (0.52) | (1.51) | (1.04) | (0.79) | (0.86) |
Free Cash Flow per Share |
0.91 | 1.46 | 1.15 | 1.37 | 2.47 | 2.67 | 0.82 | 0.54 | 1.42 | 1.33 |
Cash per Share |
2.24 | 2.16 | 3.39 | 1.93 | 3.02 | 2.49 | 1.32 | 1.04 | 0.85 | 1.33 |
Shareholders Equity per Share |
11.60 | 11.63 | 24.17 | 13.97 | 15.58 | 16.18 | 15.15 | 16.04 | 14.50 | 15.57 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.60 | 11.63 | 24.17 | 13.97 | 15.58 | 16.18 | 15.15 | 16.04 | 14.50 | 15.57 |
Free Cash Flow |
1,416.75 | 2,273.01 | 2,205.74 | 4,274.50 | 7,716.61 | 8,356.06 | 2,548.78 | 1,685.12 | 4,472.39 | 4,179.29 |
Working Capital |
(980.49) | 3,071.69 | 4,857.54 | 2,700.51 | 8,833.34 | 3,986.41 | (621.48) | 1,693.79 | 96.83 | 1,705.63 |
Capital Expenditures |
(1,013.92) | (1,127.67) | (750.57) | (1,887.21) | (1,786.14) | (1,639.58) | (4,682.18) | (3,257.66) | (2,505.01) | (2,694.15) |
Net Current Asset Value |
(10,659.25) | (9,092.22) | (50,922.69) | (51,742.43) | (47,208.90) | (43,617.60) | (38,517.90) | (36,405.84) | (31,621.74) | (32,936.34) |
EV/EBIT |
0.00 | 5.92 | 7.49 | 95.40 | 3.88 | 18.45 | 21.90 | 49.37 | 57.30 | 28.91 |
Capex to Sales |
0.06 | 0.07 | 0.04 | 0.06 | 0.06 | 0.05 | 0.16 | 0.11 | 0.08 | 0.09 |
Price to Operating Income |
0.00 | 5.10 | 6.29 | 51.18 | 2.43 | 10.92 | 14.09 | 28.96 | 35.59 | 19.81 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.42 | 0.34 | 0.21 | 0.42 | 0.38 | 0.37 | 0.39 | 0.37 | 0.39 | 0.34 |
Cash ROIC |
4.39% | 7.48% | 2.11% | 4.44% | 7.59% | 8.61% | 3.05% | 1.94% | 5.72% | 4.89% |
Accounts Receivable Turnover |
4.18 | 3.99 | 3.56 | 4.34 | 4.05 | 4.51 | 5.19 | 5.97 | 6.30 | 5.63 |
Accounts Payable Turnover |
2.72 | 2.03 | 2.32 | 3.41 | (3.03) | 2.52 | 1.96 | 2.29 | 3.02 | 3.25 |
Inventory Turnover |
2.47 | 2.22 | 1.10 | 1.26 | (1.33) | 1.34 | 1.24 | 1.26 | 1.27 | 1.20 |
Average Days of Payables |
157.18 | 176.83 | 181.14 | 106.78 | (126.22) | 170.26 | 190.48 | 140.08 | 109.84 | 114.11 |
Days of Inventory on Hand |
147.82 | 156.73 | 545.96 | 254.42 | (276.74) | 281.35 | 289.42 | 309.53 | 281.18 | 324.36 |
Average Receivables |
3,855.09 | 3,997.78 | 5,300.60 | 6,981.67 | 7,430.39 | 7,043.23 | 5,745.74 | 4,929.02 | 4,800.09 | 5,285.29 |
Average Payables |
1,911.92 | 2,200.06 | 2,554.44 | 2,939.83 | 3,082.59 | 3,913.56 | 4,699.68 | 4,291.11 | 3,458.23 | 3,190.72 |
Average Inventory |
2,106.41 | 2,010.52 | 5,398.60 | 7,934.50 | 7,037.40 | 7,339.83 | 7,446.48 | 7,823.94 | 8,191.30 | 8,626.10 |
Average Assets |
36,124.34 | 38,733.47 | 80,904.54 | 121,402.50 | 119,664.85 | 119,330.00 | 110,285.90 | 103,769.05 | 99,144.89 | 98,207.49 |
Average Common Equity |
17,409.18 | 18,141.03 | 32,314.49 | 44,982.58 | 46,079.17 | 49,624.41 | 48,803.96 | 48,607.60 | 47,984.05 | 47,409.88 |
Columns are period end dates